Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0000902664-26-001047
Filing Date
2026-02-17
Accepted
2026-02-17 13:45:45
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 8735
  Complete submission text file 0000902664-26-001047.txt   10609
Mailing Address JOSHUA DAWSON HOUSE DAWSON STREET DUBLIN 2 L2 D02 RY95
Business Address JOSHUA DAWSON HOUSE DAWSON STREET DUBLIN 2 L2 D02 RY95 353 1 437 8334
GH Research PLC (Subject) CIK: 0001855129 (see all company filings)

EIN.: 000000000 | State of Incorp.: L2 | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-92661 | Film No.: 26639371
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address D81 CALLE C SUITE 301 PMB 1202 DORADO Puerto Rico 00646
Business Address D81 CALLE C SUITE 301 PMB 1202 DORADO Puerto Rico 00646 703-963-7214
Lynx1 Capital Management LP (Filed by) CIK: 0001910456 (see all company filings)

EIN.: 851134656 | State of Incorp.: DE | Fiscal Year End: 1231
LEI: 5493003YH8Q5SHT17216
Type: SCHEDULE 13G/A